Jun 28th 2012 - Edison Investment Research today published a report on Immunodiagnostic Systems Holdings (IDH.L, LSE:IDH, LON:IDH) entitled "Fog On The Tyne". In summary, the report says:
FY12 figures show sales up 7%, but this is irrelevant as the restatement of 2011 sales makes comparisons fog-shrouded. Write-offs amount to £7.7m. The putative new CEO may either have to merge to get market traction or fatten Immunodiagnostic Systems (IDS) for a trade sale. Technically the products seem to be good, although finding independent verification is tough. The automated hypertension and 1,25-dihydroxy vitamin D assays are firsts, but IDS needs time and cash to develop the markets before DiaSorin.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »